Clinical trial
A Phase 2 Multicenter, Double-masked, Randomized, Vehicle-controlled, Parallel Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction
NCT04884243 is registered in ClinicalTrials.gov with Cloudbreak Therapeutics, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Multicenter, Double-masked, Randomized, Vehicle-controlled, Parallel Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction
- Lead sponsor
- Cloudbreak Therapeutics, LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 5, 2021
- Completion date
- August 17, 2023
- Enrollment
- 92 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.